EPRI - Electrical Power Research Institute
The Electric Power Research Institute, Inc. (EPRI), is an American independent, nonprofit organization that conducts research and development related to the generation, delivery, and use of electricity to help address challenges in electricity, including reliability, efficiency, affordability, health, safety, and the environment.
EPRI’s principal offices and laboratories are located in Palo Alto, California; Charlotte, N.C.; Knoxville, TN; and Lenox, MA.
For more information: www.epri.com
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information on GSMA activities related to electromagnetic fields please visit: https://www.gsma.com/emf
For more information: https://www.gsma.com
Pulse Biosciences® is a novel bioelectric medicine company committed to health innovation that will improve and extend the lives of patients. The company utilizes its patented groundbreaking Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS is a proprietary technology that delivers nano-second pulses of high amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. The cell-specific effects of NPS technology have been validated in a series of ongoing clinical trials. In addition, early pre-clinical evidence suggests that the NPS technology holds a promising future in immuno-oncology by demonstrating an ability to induce immunogenic cell death.
The CellFX™ System, the company’s first planned commercial product to harness the distinctive advantages of NPS technology, is a multi-application platform designed to address a broad range of dermatologic conditions. The initial commercial use of CellFX procedures will be the clearance of common skin lesions, including sebaceous hyperplasia and seborrheic keratosis– two prevalent and difficult-to-treat benign skin conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes that lead to greater overall satisfaction.
For more information: http://www.pulsebiosciences.com/